While these results are not entirely unsurprising given that adenosine—like bradykinin—is a potent vasodilator, it is interesting that the administration of selective ADORA3 agonists alleviates neuropathic sensitivity following chronic constriction injury, spared nerve injury, and spinal nerve ligation as well as in a model of cancer‐induced bone pain (Durante et al., 2021; Little et al., 2015). This evidence concerns the gene ADORA3 and cancer.